Literature DB >> 22885329

Development of an accurate index for predicting outcomes of patients with acute liver failure.

Anna Rutherford1, Lindsay Y King2, Linda S Hynan3, Chetan Vedvyas4, Wenyu Lin5, William M Lee6, Raymond T Chung7.   

Abstract

BACKGROUND & AIMS: Patients with acute liver failure (ALF) have high mortality and frequently require liver transplantation (LT); few reliable prognostic markers are available. Levels of M30, a cleavage product of cytokeratin-18 caspase, are significantly increased in serum samples from patients with ALF who die or undergo LT. We developed a prognostic index for ALF based on level of M30 and commonly measured clinical variables (called the Acute Liver Failure Study Group [ALFSG] index) and compared its accuracy with that of the King's College criteria (KCC) and Model for End Stage Liver Disease (MELD). We also validated our model in an independent group of patients with ALF.
METHODS: Serum levels of M30 and M65 antigen (the total cytokeratin-18 fragment, a marker of apoptosis and necrosis) were measured on 3 of the first 4 days following admission of 250 patients with ALF. Logistic regression was used to determine whether the following factors, measured on day 1, were associated with LT or death: age, etiology; coma grade; international normalized ratio (INR); serum pH; body mass index; levels of creatinine, bilirubin, phosphorus, arterial ammonia, and lactate; and log(10) M30 and log(10) M65. The area under the receiver operating characteristic (AUROC) was calculated for the ALFSG and other indices.
RESULTS: Coma grade, INR, levels of bilirubin and phosphorus, and log(10) M30 value at study entry most accurately identified patients who would require LT or die. The ALFSG index identified these patients with 85.6% sensitivity and 64.7% specificity. Based on comparison of AUROC values, the ALFSG Index (AUROC, 0.822) better identified patients most likely to require LT or die than the KCC (AUROC, 0.654) or MELD (AUROC, 0.704) (P = .0002 and P = .0010, respectively). We validated these findings in a separate group of 250 patients with ALF.
CONCLUSIONS: The ALFSG index, a combination of clinical markers and measurements of the apoptosis biomarker M30, better predicts outcomes of patients with ALF than the KCC or MELD.
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22885329      PMCID: PMC3480539          DOI: 10.1053/j.gastro.2012.07.113

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  25 in total

1.  New prognostic scoring model for liver transplantation in patients with non-acetaminophen-related fulminant hepatic failure.

Authors:  Yasuhiro Miyake; Kohsaku Sakaguchi; Yoshiaki Iwasaki; Hiroshi Ikeda; Yasuhiro Makino; Haruhiko Kobashi; Yasuyuki Araki; Masaharu Ando; Keiji Kita; Yasushi Shiratori
Journal:  Transplantation       Date:  2005-10-15       Impact factor: 4.939

2.  Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis.

Authors:  S Strand; W J Hofmann; A Grambihler; H Hug; M Volkmann; G Otto; H Wesch; S M Mariani; V Hack; W Stremmel; P H Krammer; P R Galle
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

3.  Gc-globulin and prognosis in acute liver failure.

Authors:  Frank V Schiødt; Lorenzo Rossaro; Richard T Stravitz; A Obaid Shakil; Raymond T Chung; William M Lee
Journal:  Liver Transpl       Date:  2005-10       Impact factor: 5.799

4.  Alpha-fetoprotein and prognosis in acute liver failure.

Authors:  Frank V Schiødt; George Ostapowicz; Natalie Murray; Raj Satyanarana; Atif Zaman; Santiago Munoz; William M Lee
Journal:  Liver Transpl       Date:  2006-12       Impact factor: 5.799

Review 5.  Apoptosis and necrosis in the liver: a tale of two deaths?

Authors:  Harmeet Malhi; Gregory J Gores; John J Lemasters
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

6.  Predictive value of arterial ammonia for complications and outcome in acute liver failure.

Authors:  V Bhatia; R Singh; S K Acharya
Journal:  Gut       Date:  2005-07-15       Impact factor: 23.059

7.  The predictive value of admission and follow up factor V and VII levels in patients with acute hepatitis and coagulopathy.

Authors:  Eran Elinav; Iddo Ben-Dov; Esther Hai-Am; Zvi Ackerman; Yishai Ofran
Journal:  J Hepatol       Date:  2005-01       Impact factor: 25.083

8.  Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury.

Authors:  Heike Bantel; Andreas Lügering; Jan Heidemann; Xandra Volkmann; Christopher Poremba; Christian P Strassburg; Michael Peter Manns; Klaus Schulze-Osthoff
Journal:  Hepatology       Date:  2004-11       Impact factor: 17.425

9.  Early indicators of prognosis in fulminant hepatic failure.

Authors:  J G O'Grady; G J Alexander; K M Hayllar; R Williams
Journal:  Gastroenterology       Date:  1989-08       Impact factor: 22.682

10.  Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus.

Authors:  Le H Song; Vu Q Binh; Dinh N Duy; Thomas C Bock; Peter G Kremsner; Adrian J F Luty; Elie Mavoungou
Journal:  J Med Virol       Date:  2004-06       Impact factor: 2.327

View more
  32 in total

1.  Development of a Model to Predict Transplant-free Survival of Patients With Acute Liver Failure.

Authors:  David G Koch; Holly Tillman; Valerie Durkalski; William M Lee; Adrian Reuben
Journal:  Clin Gastroenterol Hepatol       Date:  2016-04-13       Impact factor: 11.382

2.  Prognostic value of M30/M65 for outcome of hepatitis B virus-related acute-on-chronic liver failure.

Authors:  Su-Jun Zheng; Shuang Liu; Mei Liu; Malcolm A McCrae; Jun-Feng Li; Yuan-Ping Han; Chun-Hui Xu; Feng Ren; Yu Chen; Zhong-Ping Duan
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

3.  Serum Procalcitonin in Patients with Acute Liver Failure.

Authors:  Takaaki Sugihara; Masahiko Koda; Toshiaki Okamoto; Kenichi Miyoshi; Tomomitsu Matono; Kenji Oyama; Keiko Hosho; Jun-Ichi Okano; Hajime Isomoto
Journal:  Yonago Acta Med       Date:  2017-03-09       Impact factor: 1.641

Review 4.  Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.

Authors:  Robert J Fontana
Journal:  Gastroenterology       Date:  2013-12-31       Impact factor: 22.682

5.  Carbamoyl phosphate synthetase-1 is a rapid turnover biomarker in mouse and human acute liver injury.

Authors:  Sujith V W Weerasinghe; You-Jin Jang; Robert J Fontana; M Bishr Omary
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-06-12       Impact factor: 4.052

6.  Glycodeoxycholic acid levels as prognostic biomarker in acetaminophen-induced acute liver failure patients.

Authors:  Benjamin L Woolbright; Mitchell R McGill; Vincent S Staggs; Robert D Winefield; Parviz Gholami; Mojtaba Olyaee; Matthew R Sharpe; Steven C Curry; William M Lee; Hartmut Jaeschke
Journal:  Toxicol Sci       Date:  2014-09-19       Impact factor: 4.849

Review 7.  Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver.

Authors:  Nam-On Ku; Pavel Strnad; Heike Bantel; M Bishr Omary
Journal:  Hepatology       Date:  2016-04-04       Impact factor: 17.425

8.  Keratin 18 Is a Diagnostic and Prognostic Factor for Acute Alcoholic Hepatitis.

Authors:  Vatsalya Vatsalya; Matthew C Cave; Maiying Kong; Leila Gobejishvili; K Cameron Falkner; John Craycroft; Mack Mitchell; Gyongi Szabo; Arthur McCullough; Srinivasan Dasarathy; Svetlana Radaeva; Bruce Barton; Craig J McClain
Journal:  Clin Gastroenterol Hepatol       Date:  2019-12-04       Impact factor: 11.382

Review 9.  Drug-induced acute liver failure.

Authors:  William M Lee
Journal:  Clin Liver Dis       Date:  2013-09-04       Impact factor: 6.126

Review 10.  Liver transplantation in acute liver failure: A challenging scenario.

Authors:  Manuel Mendizabal; Marcelo Oscar Silva
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.